Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCQX: AVXL) today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present at the 17th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2015 at 11:30 a.m. ET at the Waldorf-Astoria Hotel, Louis XVI room, in New York, NY. Investors may view Dr. Missling’s presentation via live webcast on the BIO website or access an archived version via Anavex.com.
Dr. Missling’s presentation will include an overview of Anavex’s advancing clinical development programs including the current Phase 2a adaptive trial evaluating ANAVEX 2-73 and ANAVEX PLUS in Alzheimer’s patients. The Company began trial enrollment in January 2015 and has since reported dosing of the first patient. Topline data results are expected to be released in the third quarter of 2015.
The 17th Annual BIO CEO & Investor Conference is hosted by the Biotechnology Industry Organization. It is the largest independent investor conference focused on established and emerging publicly traded and select private biotech companies.